Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, ...
GH Research PLC has provided updates on its GH001 treatment for depression, reporting completion of the Open-Label Extension analysis that shows a 73% remission rate at six months without serious ...
Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissue drug levels exceeded target thresholds ...
The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback